FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1512014737> ?p ?o ?g. }

• W1512014737 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAWe have previously demonstrated that type II interleukin 1 receptor (IL1R2), which is an IL-1 decoy receptor and inhibits exogenous IL-1 signaling, activates the expression of several proinflammatory cytokines. We also found that enhanced expression of IL1R2 promotes tumor growth and increases tumor angiogenesis through activated IL-6/VEGF-A signalings. Recently, we observed a close association of enhanced expression of IL1R2 and Regorafenib resistance in colorectal cancer (CRC) cell lines. Regorafenib is the newly approved multi-kinase inhibitor used for treatment of late-stage metastatic CRC by US FDA. To have a better use of Regorafenib against CRC, we conducted experiments to understand the mechanism underlying which IL1R2 is involved in Regorafenib resistance. In the present study, we demonstrated that silencing of IL1R2 in HT29 cell overcame its resistance to Regorafenib whereas ectopic expression of IL1R2 decreased the sensitivity of HCT116 cell to Regorafenib in in vitro and in vivo systems. IL1R2 silencing also enhanced the apoptotic proteins expression in Regorafenib-treated cells. In addition, we have established Regorafenib-resistant DLD-1 colon cancer cells by growing them in the presence of Regorafenib. Consistently, higher IL1R2 expression was found in Regorafenib-resistant cells than the parental cells. Mechanistically, we observed that Regorafenib treatment significantly resulted in enhanced expression of extracellular-signal-regulated kinase (Erk), which functions as a survival factor, in IL1R2-overexpressing cells. Therefore, pretreatment of IL1R2-overepressing CRC cells with Erk inhibitor, U0126, reversed their Regorafenib resistance, suggesting that Erk signaling cascade is crucial in Regorafenib resistance resulted from IL1R2 overexpression. Taken together, our present study suggested that combination of Regorafenib and Erk inhibitor is a rationale regime to overcome IL1R2 overexpression-induced Regorafenib resistance in CRC patients, but also IL1R2 is a potential biomarker for colon cancer therapy.Citation Format: Ai-Chung Mar, Chun-Ho Chu, Te-Chang Lee. Erk inhibitor overcomes type II interleukin 1 receptor, a decoy receptor, associated Regorafenib resistance in colorectal carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1714. doi:10.1158/1538-7445.AM2014-1714" @default.
• W1512014737 created "2016-06-24" @default.
• W1512014737 creator A5001017278 @default.
• W1512014737 creator A5004560801 @default.
• W1512014737 creator A5025326455 @default.
• W1512014737 date "2014-09-30" @default.
• W1512014737 modified "2023-09-26" @default.
• W1512014737 title "Abstract 1714: Erk inhibitor overcomes type II interleukin 1 receptor, a decoy receptor, associated Regorafenib resistance in colorectal carcinoma" @default.
• W1512014737 doi "https://doi.org/10.1158/1538-7445.am2014-1714" @default.
• W1512014737 hasPublicationYear "2014" @default.
• W1512014737 type Work @default.
• W1512014737 sameAs 1512014737 @default.
• W1512014737 citedByCount "1" @default.
• W1512014737 countsByYear W15120147372017 @default.
• W1512014737 crossrefType "proceedings-article" @default.
• W1512014737 hasAuthorship W1512014737A5001017278 @default.
• W1512014737 hasAuthorship W1512014737A5004560801 @default.
• W1512014737 hasAuthorship W1512014737A5025326455 @default.
• W1512014737 hasConcept C121608353 @default.
• W1512014737 hasConcept C126322002 @default.
• W1512014737 hasConcept C184235292 @default.
• W1512014737 hasConcept C2776248978 @default.
• W1512014737 hasConcept C502942594 @default.
• W1512014737 hasConcept C526805850 @default.
• W1512014737 hasConcept C57074206 @default.
• W1512014737 hasConcept C71924100 @default.
• W1512014737 hasConcept C86803240 @default.
• W1512014737 hasConcept C95444343 @default.
• W1512014737 hasConcept C98274493 @default.
• W1512014737 hasConceptScore W1512014737C121608353 @default.
• W1512014737 hasConceptScore W1512014737C126322002 @default.
• W1512014737 hasConceptScore W1512014737C184235292 @default.
• W1512014737 hasConceptScore W1512014737C2776248978 @default.
• W1512014737 hasConceptScore W1512014737C502942594 @default.
• W1512014737 hasConceptScore W1512014737C526805850 @default.
• W1512014737 hasConceptScore W1512014737C57074206 @default.
• W1512014737 hasConceptScore W1512014737C71924100 @default.
• W1512014737 hasConceptScore W1512014737C86803240 @default.
• W1512014737 hasConceptScore W1512014737C95444343 @default.
• W1512014737 hasConceptScore W1512014737C98274493 @default.
• W1512014737 hasLocation W15120147371 @default.
• W1512014737 hasOpenAccess W1512014737 @default.
• W1512014737 hasPrimaryLocation W15120147371 @default.
• W1512014737 hasRelatedWork W1500488830 @default.
• W1512014737 hasRelatedWork W1578012610 @default.
• W1512014737 hasRelatedWork W1689099092 @default.
• W1512014737 hasRelatedWork W1999154148 @default.
• W1512014737 hasRelatedWork W2039828509 @default.
• W1512014737 hasRelatedWork W2077940715 @default.
• W1512014737 hasRelatedWork W2080910078 @default.
• W1512014737 hasRelatedWork W2155581805 @default.
• W1512014737 hasRelatedWork W2404643288 @default.
• W1512014737 hasRelatedWork W2475462518 @default.
• W1512014737 hasRelatedWork W2499892494 @default.
• W1512014737 hasRelatedWork W2500018037 @default.
• W1512014737 hasRelatedWork W2507084326 @default.
• W1512014737 hasRelatedWork W2565853215 @default.
• W1512014737 hasRelatedWork W2566758544 @default.
• W1512014737 hasRelatedWork W2567702713 @default.
• W1512014737 hasRelatedWork W2791815945 @default.
• W1512014737 hasRelatedWork W2887445794 @default.
• W1512014737 hasRelatedWork W3095108140 @default.
• W1512014737 hasRelatedWork W3206125616 @default.
• W1512014737 isParatext "false" @default.
• W1512014737 isRetracted "false" @default.
• W1512014737 magId "1512014737" @default.
• W1512014737 workType "article" @default.